You must have Javascript enabled and Flash 8.0 or above to view the Patient Stories.
Please download Flash here

Welcome to the Pulmozyme Community, a place for people of all ages to connect and learn about life with cystic fibrosis. There are stories, games, links, tips, and much more.

For those 13 and over, you can also read about inspiring individuals with cystic fibrosis who have taken charge of their lives through a healthy diet, consistent exercise, and a faithful adherence to their medical regimen. Be a part of this growing community; Share My Story by pressing the button on the right.

5-8 Years Old

Explore our colorful interactive storybooks about cystic fibrosis. It's the perfect introduction for children in this age group.

9-12 Years Old

Learning about cystic fibrosis doesn't have to be boring! Play some of these fun CF-themed video games to see how.

13-17 Years Old

It's tough being a teenager sometimes, and having cystic fibrosis doesn't make it any easier. That's why we put together a bunch of real teen profiles, some helpful life tips, and a few external links we think you might like.

18+ Years Old

So you've made it out of high school, and you might be thinking of college, a career, and living on your own. What now? For answers, start your search here. It's your life now, live it to the fullest.

Parents and Caregivers

Your child may have just been diagnosed with cystic fibrosis, and there is so much to learn. Use this resource to find links, testimonials, and tips that can help make your child's future as bright as possible.

Indication and Usage

Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.

Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF. When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.

Pediatric Use

Because of the limited experience with the administration of Pulmozyme to patients younger than 5 years of age, its use should be considered only for those patients in whom there is a potential for benefit in pulmonary function or in risk of respiratory tract infection.

Important Safety Considerations

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to ≤10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. There were more reports of cough, moderate to severe cough, runny nose, and rash in the younger group of patients. Other reported events tended to be of mild to moderate severity. The kind of side effects reported was similar to that of Pulmozyme when used in the larger trials that studied older patients.

For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.